MDMA Therapy 2026 Update: Where Things Stand After the FDA Rejection
The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD in August 2024, and as of mid-2026 that decision stands. MDMA remains a Schedule I...
Microdosing Protocols in 2026: Fadiman, Stamets, and the Clinical Data
The two most widely followed microdosing protocols are the Fadiman protocol (one day on, two days off) and the Stamets Stack (four or five days on,...
Psilocybin Eating Disorder Treatment: Early Evidence and Cautions
Psilocybin eating disorder treatment is an emerging area of clinical research, with early trials in anorexia nervosa showing that the compound is well-tolerated and may help...
Psilocybin and the Aging Brain: What the Research Shows So Far
Research into psilocybin aging effects is accelerating, with preclinical studies pointing to neuroplasticity promotion, reduced neuroinflammation, and improvements in longevity biomarkers. The findings are genuinely interesting,...
How to Talk to Your Doctor About Psychedelic Therapy
Talking to your doctor about psychedelic therapy is one of the most common points where people get stuck. This guide walks you through how to frame...
5-MeO-DMT Therapy: What the Research Shows and Why Risks Are Real
5-MeO-DMT therapy is attracting serious interest from researchers, executives, and people seeking relief from depression, anxiety, and trauma. The compound is potent, fast-acting, and increasingly the...
Psilocybin OCD Treatment: What the Early Research Shows
Psilocybin OCD treatment is a small but growing area of clinical research, with early data suggesting meaningful symptom reductions for people who have not responded to...
Psychedelic Therapy Contraindications: Who Should Pause First
Psychedelic therapy contraindications include a personal history of psychosis or mania, current lithium use, certain cardiac conditions, and active suicidal ideation with intent. Some of these...
Executive Burnout Psychedelic Therapy: What the Research Shows
Executive burnout psychedelic therapy is moving from the research margins into serious clinical conversation. A growing body of peer-reviewed evidence suggests that psilocybin-assisted therapy can reduce...
Psilocybin PTSD Therapy: What the 2026 Clinical Evidence Shows
Psilocybin PTSD therapy is no longer a fringe concept. A growing body of clinical research, including Phase 2 trials published in 2025, shows that a single...
Ready to take the next step?
Start with a complimentary conversation, or take the two-minute self-evaluation to see if this is your moment.